comparemela.com
Home
Live Updates
Investegate |HMNC Holding GmbH Announcements | HMNC Holding GmbH: First patient dosed in second Phase 2 add-on Ketamine Trial in Treatment-Resistant Depression (TRD) : comparemela.com
Investegate |HMNC Holding GmbH Announcements | HMNC Holding GmbH: First patient dosed in second Phase 2 add-on Ketamine Trial in Treatment-Resistant Depression (TRD)
Investegate announcements from HMNC Holding GmbH, First patient dosed in second Phase 2 add-on Ketamine Trial in Treatment-Resistant Depression (TRD)
Related Keywords
Switzerland ,
Germany ,
South Africa ,
Australia ,
Pratteln ,
Switzerland General ,
Munich ,
Bayern ,
Schopfheim ,
Baden Wüberg ,
German ,
Swiss ,
Anne Donohoe ,
Sophia Bashford ,
Develco Pharma ,
Alexander Schmidt Europe ,
Hans Eriksson ,
Ketabon Program ,
Holding Gmb ,
Brain Health ,
Ketamine Trial ,
Treatment Resistant Depression ,
Chief Medical Officer ,
Swiss Based Develco Pharma ,
Depression Rating Scale ,
Major Depressive Disorder ,
Investegate Announcements ,
Investegate Company Announcements ,
Hmnc Holding Gmbh ,
Lobenewswire ,
Lobenewswire And Globenewswire ,
Nw ,
comparemela.com © 2020. All Rights Reserved.